Compare AbbVie Inc (ABBV) vs Adobe Systems Inc (ADBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Adobe Systems Inc — how do they compare? AbbVie Inc trades at $253.81 (market cap $449.91B), while Adobe Systems Inc trades at $220.6 (market cap $88.06B). The key difference: AbbVie Inc is far larger — about 5.1× Adobe Systems Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ABBV | ADBE | |
|---|---|---|
Market Cap | $449.91B | $88.06B |
Sector | Health | Technology |
52-Week High | $261.07 | $382.24 |
52-Week Low | $184.85 | $193.41 |
Enterprise Value | $513.38B | $89.50B |
Dividend Yield | 2.72% | — |
Volume | — | 5,187,646 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Adobe (ADBE) trades at $220.35, up 1.05% with a bullish technical signal. The company reported strong Q1 2026 earnings of $5.96 EPS, beating estimates, and maintains robust profitability with 89.4% gross margins. Revenue growth accelerated to $23.77B in 2025, while valuation ratios remain attractive with P/E at 12.67. Recent institutional buying activity contrasts with some analyst concerns about AI competition.
Adobe presents a compelling investment case with strong fundamentals and growth trajectory, though AI disruption risks and recent stock volatility warrant caution. The consensus price target of $246.75 suggests 12% upside potential, supported by consistent earnings beats and expanding cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →
